Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer

Gahan, P. B.

doi:10.1007/s13167-010-0021-6

Cited by 24 publications

(13 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current efforts are focused on the development of pathologyspecific diagnostic tools that could enable the precise estimation of a predisposition to breast cancer, to predict and monitor disease progression followed by personalized therapy planning. The most promising minimally invasive and pathology-specific approaches are the detection of circulating nucleic acids and protein/metabolites profiling in blood serum-circulating leukocytes [3][4][5][6][7][8][9][10][11][12].…”

Section: Identification Of the Affected Pathwaysmentioning

confidence: 99%

Noninvasive Subcellular Imaging in Breast Cancer Risk Assessment: Construction of Diagnostic Windows

Yeghiazaryan

Cebioglu

Braun

et al. 2011

Personalized Medicine

View full text Add to dashboard Cite

The qualitative comet assay is an innovative approach for breast cancer risk assessment that can be utilized for the screening of highly predisposed individuals among patients with benign breast alterations. Pathology-specific comet patterns have been identified as the robust biomarker for breast cancer risk. Mathematic model-based diagnostic windows have been constructed for their clinical application.

show abstract

Section: Identification Of the Affected Pathwaysmentioning

confidence: 99%

Noninvasive Subcellular Imaging in Breast Cancer Risk Assessment: Construction of Diagnostic Windows

Yeghiazaryan

Cebioglu

Braun

et al. 2011

Personalized Medicine

View full text Add to dashboard Cite

show abstract

“…Nonetheless, a few general trends can be identified, namely: (i) according to the personalized medicine, a patient's health should be based on the specific characteristics of an individual, including age, gender, height, weight, information on gene expressions, etc. This would help estimate, for example, the risk of cancer, that of heart disease, or of diabetes, and assist in planning therapy; (ii) great efforts are being made to select segments of DNA as well as of RNA [12][13][14][15][16] or even to determine the diseaseindicator role of circulating tumor-derived nucleic acids in cancer patients [17]. These nucleic acids may serve as tumor markers; (iii) the pharmacogenetics of drugmetabolizing enzymes is responsible for a significant portion of drug-induced toxicity.…”

Section: A Look Into the Futurementioning

confidence: 99%

Basics in Laboratory Medicine: Past, Present, and Future

Debreczeni

Kovácsay

Nagy

2012

Analytical Techniques for Clinical Chemistry

View full text Add to dashboard Cite

“…12. The possibility to use DNA and RNA, which circulate in plasma and serum, to monitor treatment and for prognosis in oncology are reviewed [12]. Different levels were found between primary tumors and metastases.…”

Section: The Importance Of Individual Clinical Responses Tomentioning

confidence: 99%

Cancer diagnostics and treatment: are we ready to implement PPPM?

Desiderio

2010

EPMA Journal

View full text Add to dashboard Cite

The scientific community is always excited whenever a new journal appears in the open scientific literature. Such was the case when the first issue of the EPMA Journal of International Reviews in Predictive, Preventive and Personalized Medicine (PPPM) appeared in 2010.This present issue focuses on PPPM in Cancer, and it contains a spectrum of topics that covers the range from basic research, via clinical research, to potential implementation. Each review focuses on one or a reasonable combination of the three main topics embodied in the EPMA journal, and highlights the predictive, preventive, and personalized aspects of cancer treatment. It is clear from the scientific literature, in general, and in each one of the reviews in this issue, in particular, that the next quantum leap in clinical science now derives explicitly from one or more of those three features of medicine: accurate prediction, efficacious prevention, and detailed personalized treatment. The objective of this journal and of this issue on cancer is to present state-of-the-art results from researchers from around the world, and to provide timely reviews of cutting-edge basic research, clinical research, and clinical results. The reviews will range from the molecular level (DNA, RNA, proteins, metabolites), the cellular level, clinical research, and clinical practice.A brief overview follows of each topic that appears in this current issue of PPPM in Cancer. These reviews cover the following areas of research: the "First Do No Harm" concept; the shift from correlative to predictive oncology; selenium and oxidative stress in cancer; BRCA1 and BRCA2 gene mutations; a proposal for non-invasive proteomics in breast cancer; gene-expression profiling in breast cancer; proteomics and nitroproteomics of pituitary adenomas; epidemiological analysis of gastric adenocarcinomas; endoscopic diagnosis for the early detection of gastrointestinal cancer; fluoropyrimidine toxicity and polymorphisms of the dihydropyrimidine dehydrogenase gene; and circulating DNA and RNA.

show abstract

Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer

Cited by 24 publications

References 86 publications

Noninvasive Subcellular Imaging in Breast Cancer Risk Assessment: Construction of Diagnostic Windows

Noninvasive Subcellular Imaging in Breast Cancer Risk Assessment: Construction of Diagnostic Windows

Basics in Laboratory Medicine: Past, Present, and Future

Cancer diagnostics and treatment: are we ready to implement PPPM?

Contact Info

Product

Resources

About